Systemic Therapy Update on ¹⁷⁷Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A

JCO Oncol Pract. 2023 Mar;19(3):132-135. doi: 10.1200/OP.22.00753. Epub 2023 Jan 24.

Authors

Rohan Garje¹, Thomas A Hope², R Bryan Rumble³, Rahul A Parikh⁴; Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Guideline Expert Panel

Affiliations

¹ Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
² University of California, San Francisco, San Francisco, CA.
³ American Society of Clinical Oncology, Alexandria, VA.
⁴ University of Kansas Medical Center, Kansas City, KS.

PMID: 36693228
DOI: 10.1200/OP.22.00753

No abstract available

MeSH terms

Dipeptides
Humans
Lutetium*
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant* / pathology

Substances

PSMA-617
Lutetium
Prostate-Specific Antigen
Dipeptides